非唑奈坦治疗绝经相关中重度血管舒缩症状的疗效与安全性:一项3期随机对照试验
这项双盲、安慰剂对照、12周3期试验(含40周活性治疗扩展期)纳入40至65岁、每日平均至少7次中重度血管舒缩症状的绝经女性,随机接受安慰剂、非唑奈坦30 mg或45 mg每日一次治疗12周。两种剂量在第4周和第12周均较安慰剂显著降低血管舒缩症状频率和严重程度,改善在第1周即出现并维持至第52周;严重治疗中出现的不良事件罕见。
要点
- 非唑奈坦30 mg和45 mg在第4周及第12周均较安慰剂显著降低血管舒缩症状频率和严重程度。
- 血管舒缩症状频率和严重程度的改善在第1周即可观察到,并维持至第52周。
- 严重治疗中出现的不良事件罕见,非唑奈坦30 mg、45 mg和安慰剂组报告率分别为2%、1%和0%。
核心结论
- 每日非唑奈坦30 mg和45 mg对治疗绝经相关中重度血管舒缩症状有效且耐受性良好。
研究设计与样本
- 双盲、安慰剂对照、12周3期试验,含40周活性治疗扩展期(NCT04003142;SKYLIGHT 2)。
- 纳入40至65岁、每日平均至少7次中重度血管舒缩症状的女性,随机接受每日一次安慰剂、非唑奈坦30 mg或45 mg治疗12周。
- 完成12周治疗者再随机接受非唑奈坦30 mg或45 mg治疗额外40周。
主要发现
- 血管舒缩症状频率第4周较安慰剂的最小二乘均值(标准误)降幅:非唑奈坦30 mg为-1.82(0.46;P < .001),45 mg为-2.55(0.46;P < .001)。
- 血管舒缩症状频率第12周较安慰剂的最小二乘均值(标准误)降幅:非唑奈坦30 mg为-1.86(0.55;P < .001),45 mg为-2.53(0.55;P < .001)。
- 血管舒缩症状严重程度第4周较安慰剂的最小二乘均值(标准误)降幅:非唑奈坦30 mg为-0.15(0.06;P < .05),45 mg为-0.29(0.06;P < .001)。
- 血管舒缩症状严重程度第12周较安慰剂的最小二乘均值(标准误)降幅:非唑奈坦30 mg为-0.16(0.08;P < .05),45 mg为-0.29(0.08;P < .001)。
- 严重治疗中出现的不良事件报告率:非唑奈坦30 mg组2%、非唑奈坦45 mg组1%、安慰剂组0%。
关键数值与推荐
- 共同主要疗效终点为血管舒缩症状频率和严重程度从基线至第4周和第12周的日均变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause. OBJECTIVE: We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause. METHODS: In this double-blind, placebo-controlled, 12-week phase 3 trial with a 40-week active treatment extension (NCT04003142; SKYLIGHT 2), women aged 40 to 65 years with minimum average 7 moderate to severe VMS/day were randomized to 12 weeks of once-daily placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Completers were rerandomized to fezolinetant 30/45 mg for 40 additional weeks. Coprimary efficacy endpoints were mean daily change from baseline to week 4 (W4) and W12 in VMS frequency and severity. Safety was also assessed. RESULTS: Both fezolinetant doses statistically significantly reduced VMS frequency/severity at W4 and W12 vs placebo. For VMS frequency, W4 least squares mean (SE) reduction vs placebo: fezolinetant 30 mg, -1.82 (0.46; P < .001); 45 mg, -2.55 (0.46; P < .001); W12: 30 mg, -1.86 (0.55; P < .001); 45 mg, -2.53 (0.55; P < .001). For VMS severity, W4: 30 mg, -0.15 (0.06; P < .05); 45 mg, -0.29 (0.06; P < .001); W12: 30 mg, -0.16 (0.08; P < .05); 45 mg, -0.29 (0.08; P < .001). Improvement in VMS frequency and severity was observed by W1 and maintained through W52. Serious treatment-emergent adverse events were infrequent, reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively. CONCLUSION: Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.
引用
- Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 2023. PMID: 36734148. doi:10.1210/clinem/dgad058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。